Current diagnostic evaluation of autosomal dominant polycystic kidney disease

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 12, 2008, Pages 767-773

  Wołyniec, Wojciech ^a,b   Jankowska, Magdalena Maria ^a   Król, Ewa ^a   Czarniak, Piotr ^a   Rutkowski, Bolesław ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b Klinika Immunologii   (Poland)

Author keywords

Autosomal dominant polycystic kidney disease; Chronic kidney disease; Ravine criteria renal cysts; Renal ultrasound examination

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; FATTY ACID BINDING PROTEIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; POLYCYSTIN 1; POLYCYSTIN 2;

ALBUMINURIA; ANEURYSM; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT INHERITANCE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE MARKER; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY CYST; KIDNEY FAILURE; KIDNEY HYPERTROPHY; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; KIDNEY TUBULE DISORDER; LIVER CYST; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; RADIODIAGNOSIS; REVIEW; STONE FORMATION; URINARY TRACT HEMORRHAGE; URINARY TRACT INFECTION;

EID: 58449090592     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.552     Document Type: Review

References (36)

1. Rizk D, Chapman AR. Core Curriculum in nephrology. Cystic and Inherited Kidney Diseases. Am J Kidney Dis. 2003; 42; 1305-1317.
2. Hateboer N, v Dijk MA, Bogdanova N, et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet. 1999; 353:103-107.
3. Torres VE, Hanis PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007; 369:1287-1301.
4. Rózański J, Myślak M, Domański L, et al. [Clinical course of the autosomal dominant polycystic kidney disease]. Pol Arch Med Wewn. 2000; 104: 525-531. Polish.
5. Pei Y. Diagnostic approach in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2006; 1: 1108-1114.
6. Chodorowski Z, Jungowska-Jarosz A, Pȩtlak O. [Comparative studies on the diagnostic role of urography, scintigraphy and renal arteriography in autosomal dominant polycystic kidney disease]. Wiad Lek. 1983; 36: 1675-1679. Polish.
7. Nahm AN, Henriquez DE, Ritz E. Renal cystic disease (ADPKD and ARPKD). Nephrol Dial Transplant. 2002; 17: 311-314.
8. Shamshirsaz A, Bekheirnia RM, Kamgar M, et al. Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int. 2005; 68: 2218-2224.
9. Ravine D, Gibson RN, Walker RG, et al. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994; 343: 824-827.
10. Ravine D, Gibson RN, Donlan J, et al. An ultrasound renal cyst prevalence survey: specificity data for inherited renal cystic diseases. Am J Kidney Dis. 1993; 22: 803-807.
11. Demetriou K, Tziakouri C, Anninou K, et al. Autosomal dominant polycystic kidney disease - type 2. Ultrasound, genetic and clinical correlations. Nephrol Dial Transplant. 2000; 15: 205-211.
12. Nascimento AB, Mitchell DG, Zhang XM, et al. Rapid MR Imaging detection of renal cysts: age-based standards. Radiology. 2001; 221: 628-632.
13. Dai B, Mei CL. Research on autosomal dominant polycystic kidney disease in China. Chin Med J. 2006; 119:1915-1924.
14. Zhao X, Paterson AD, Zahirieh A, et al. Molecular diagnostic in autosomal dominant polycystic kidney disease: utility and limitations. Clin J Am Soc Nephrol. 2008; 3:146-152.
15. Torres VR. Vasopressin antagonists in polycystic kidney disease. Kidney Int. 2005; 68: 2405-2418.
16. Spineter-Sokolowska E, Liberek T, Brylowska A, et al. [Acquired cysts of the kidney in patients treated with long-term dialysis], Pol Arch. Med Wewn. 1994; 92; 243-249. Polish.
17. Jankowska MM, Jankowski M, Debska-Ślizień A, et al. Acquired cystic kidney disease in clinical practice. Nefrol Dializoter Pol. 2007; 11: 118-120.
18. Auranen M, Ala-Mello S, Turunen JA, et al. Further evidence for linkage of autosomal-dominant medullary cystic disease on chromosome 1 q21. Kidney Int. 2001; 60: 1225-1232.
19. Kuczak M, Domański L, Ciechanowski K. [Sponge kidney - terapeutic course - case report]. Pol Arch Med Wewn. 2005; 114: 887-890. Polish.
20. Ruggenenti P, Remuzzi A, Ondei P, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 2005; 68:206-216.
21. Bae KT, Commean PK, Lee J. Volumetric measurement of renal cysts and parenchymal using MRI: phantoms and patients with polycystic kidney diseases. J Comput Assist Tomogr. 2000; 24:614-619.
22. Perrone R. Imaging progression in polycystic kidney disease. N Eng J Med. 2006; 354: 2181-2183.
23. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006; 354: 2122-2130.
24. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003; 64: 1035-1045.
25. Sise C, Kusaka M, Wetzel LH, et al. Volumetric determination of progression in autosomal dominant polycystic kidney diseases by computed tomography. Kidney Int. 2000; 58: 2492-2501.
26. Brosnahan GM. Volume progression in polycystic kidney disease (letter to the editor). N Engl J Med. 2006; 355; 733.
27. Brkljacic B, Sabljar-Matovinovic M, Putarek K, et al. Renal vascular resistance in autosomal dominant polycystic kideny disease. Evaluation with color Doppler ultrasound. Acta Radiol. 1997; 38: 840-846.
28. Ramunni A, Saracino A, Esposito T, et al. Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease. Hypertens Res. 2004; 27:221-225.
29. Kondo A, Akakura K, Ito H. Assessment of renal function with color Doppler ultrasound in autosomal domianant polycystic kidney disease. Int J Urol. 2001; 8: 95-98.
30. King BF, Torres VE, Brummer ME, et al.; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP): Magnetic resonance measurements of renal blood flow as a marker of disease severity in autosomal-dominant polycystic kidney disease. Kidney Int. 2003; 64: 2214-2221.
31. Martinez-Vea A, Gutierrez C, Bardaji A, et al. Microalbuminuria in normotensive patients with autosomal-dominant polycystic kideny disease. Scand J Urol Nephrol. 1998; 32: 356-359.
32. Nakamura T, Sugaya T, Kawagoe Y, et al. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci. 2005; 330:161-165.
33. Bolignano D, Coppolino G, Campo S, et al. Neutrophil gelatinase-asso- ciated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol. 2007; 27: 373-378.
34. Casal JA, Hermida J, Lens XM, et al. A comparative study of three kidney biomarker tests in autosomal-dominant polycystic kidney disease. Kidney Int. 2005; 68: 948-954.
35. Jasik P, Sulowicz W, Kraśniak A, et al. [Current opinions of etiology and pathogenesis of autosomal dominant polycystic kidney disease (ADPKD). Part II: others than genetic factors which have an influence on the course of the disease and selected clinical problems]. Przegl Lek. 1998; 55: 599-606. Polish.
36. Ravine D, Walker RG, Gibson RN, et al. Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease. Lancet. 1992; 340: 1330-1333.